Overton FDA Nomination Withdrawn Before Senate Vote

The Trump administration pulled Heidi Overton's nomination to lead the Food and Drug Administration hours before a pivotal Senate committee vote.

Updated on Nov. 20, 2026 in Biotech

Overton FDA Nomination Withdrawn Before Senate Vote

Live Poll

Do you trust the federal government to pick the right leader for the FDA?

The Trump administration withdrew the nomination of Heidi Overton to become the next FDA commissioner, hours before a pivotal Senate committee vote. The move comes as the agency faces leadership uncertainty and a separate setback in drug regulation.

Why it matters

The FDA commissioner oversees approval of new drugs and medical products used by Americans, so an unfilled top post can shape the pace of regulatory decisions. The withdrawal leaves the agency's leadership path unclear at a time of heightened scrutiny over drug approvals.

The nomination was withdrawn hours before a pivotal Senate committee vote, with no vote count or replacement nominee identified. The FDA also rejected a lung cancer drug from Summit Therapeutics and Akeso, though the stated reasons were not detailed.

The players

Heidi Overton

Heidi Overton is a public official whose nomination to lead the Food and Drug Administration was withdrawn by the Trump administration.

Summit Therapeutics

Summit Therapeutics is a U.S.-based biotechnology company developing cancer treatments, including a lung cancer drug the FDA rejected.

Akeso

Akeso is a Chinese drugmaker that co-developed a lung cancer drug the FDA rejected alongside Summit Therapeutics.

The details

The Trump administration withdrew its nomination of Heidi Overton to become FDA commissioner, a move that came hours before a pivotal Senate committee vote. Separately, the FDA rejected a lung cancer drug developed by U.S.-based Summit Therapeutics and Chinese drugmaker Akeso.

Timeline

  1. Nomination withdrawn hours before a pivotal Senate committee vote in Washington, D.C.

Big Picture

The FDA's rejection of a lung cancer drug from Summit Therapeutics and Akeso arrives as the agency's commissioner post sits vacant, following the withdrawal of Heidi Overton's nomination. Both developments bear on how the agency's approval pipeline for oncology drugs will be run.

Patients awaiting new lung cancer treatments may face delays if the rejected drug is not approved on a revised timeline. The unresolved FDA leadership post could affect how quickly future drug applications are decided.

The takeaway

Leadership changes at the FDA can ripple into which treatments reach patients and how quickly. Readers tracking cancer drugs should watch for the agency's next commissioner nominee and any resubmission of the rejected therapy.

Further reading

For more on drug development and regulatory decisions, explore Biotech coverage.

Source note: This article includes information reported by STAT.

Live Poll

Do you trust the federal government to pick the right leader for the FDA?